FDAnews
www.fdanews.com/articles/206836-seekin-receives-ce-mark-for-its-seekincare-pan-cancer-early-detection-test

SeekIn Receives CE Mark for Its SeekInCare Pan Cancer Early Detection Test

March 4, 2022

Shenzhen, China-based SeekIn has received a CE mark for its SeekInCare cancer detection kit.

The artificial intelligence-based diagnostic tool draws on private and public data to identify cancer DNA and protein signals in blood samples and trace them back to the tissue of origin.

The detection kit uses patented algorithms that reduce background “noise” and reveal the cancer signals in blood samples. SeekIn says the kit can detect dozens of cancer types at high specificity.

View today's stories